Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2019-12-08
Target enrollment:
Participant gender:
Summary
The study is to evaluate the efficacy and safety of Apatinib for later treatment of
patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal
carcinoma), including overall survival (OS), distant metastasis-free survival (DMFS) and
locoregional relapse-free survival (LRRFS); the relationship between EBV DNA copy number and
survival after radiotherapy or radiochemotherapy; Quality of life score (QoL); evaluation of
drug safety.
Phase:
Phase 2
Details
Lead Sponsor:
Guilin Medical University, China
Collaborators:
Guangxi Naxishan Hospital National Hospital of Guangxi Zhuang Autonomous Region Wuzhou Red Cross Hospital